Results 1 to 10 of about 529,540 (301)

Anti-vascular endothelial growth factor therapies in ophthalmology. [PDF]

Med Hypothesis Discov Innov Ophthalmol
Background: Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide. The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies has dramatically changed the management of these conditions, offering targeted treatment ...
Koksaldi S, Karti O, Saatci AO.
europepmc   +4 more sources

Newer anti-vascular endothelial growth factor agents

TNOA Journal of Ophthalmic Science and Research, 2020
Ocular angiogenesis is a major cause of ocular morbidity worldwide. Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and vascular permeability with diverse roles both during the development and adulthood. This is believed
Priya Rasipuram Chandrasekaran
doaj   +2 more sources

Pleurodesis Is Inhibited by Anti-Vascular Endothelial Growth Factor Antibody

Chest, 2005
The intrapleural injection of transforming growth factor (TGF)-beta2 produces pleurodesis in rabbits associated with large pleural effusions. This study investigated whether anti-vascular endothelial growth factor (VEGF) antibody has any effect on the fluid production or the pleurodesis induced by TGF-beta2.Three groups of seven New Zealand white ...
Ioannis Kalomenidis, Richard W Light
exaly   +4 more sources

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders

Pharmaceuticals, 2023
Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal neovascularization as well as retinal vascular leakage leading to macular edema.
Abraham Hang, Samuel Feldman, Aana P. Amin, Jorge A. Rivas Ochoa, Susanna S. Park   +4 more
doaj   +3 more sources

Anti-Vascular Endothelial Growth Factor Combined with Dexamethasone Implant Therapy for Macular Edema: A Randomized Controlled Trial [PDF]

Drug Design, Development and Therapy
Yunxi Ma, Junwen Wang, Mingzhu Yuan, Zimeng Zeng, Yuhe Tan, Lu Cao, Xufang Sun Department of Ophthalmology, Hubei Key Laboratory of Otolaryngologic and Ophthalmic Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and ...
Ma Y, Wang J, Yuan M, Zeng Z, Tan Y, Cao L, Sun X   +6 more
doaj   +2 more sources

Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

International Journal of Molecular Sciences, 2014
Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as
Markus Wehland, Daniela G Grimm, Nils E Magnusson   +2 more
exaly   +4 more sources

Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor–specific inhibitor

Tumor Biology, 2017
Vascular endothelial growth factor receptor-2 is a dynamic target for therapeutic intervention in various types of cancers. This study was aimed to explore the anti-angiogenic activity of a novel vascular endothelial growth factor receptor–specific ...
Appu Rathinavelu, Khalid Alhazzani, Sivanesan Dhandayuthapani, Thanigaivelan Kanagasabai   +3 more
doaj   +2 more sources

Anti-vascular endothelial growth factor in ophthalmology

Indian Journal of Ophthalmology, 2009
Sinha Rajesh, Choudhary Sunil, Sinha Subijoy, Vashisht Nagender, Kumar Chandrashekhar   +4 more
doaj   +2 more sources

Anti-vascular endothelial growth factor for neovascular glaucoma [PDF]

Cochrane Database of Systematic Reviews, 2009
Neovascular glaucoma (NVG) is a potentially blinding secondary glaucoma. It is caused by the formation of abnormal new blood vessels which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) agents are specific inhibitors of the primary mediators of neovascularization.
Arathi, Simha, Andrew, Braganza, Lekha, Abraham, Prasanna, Samuel, Kristina, Lindsley   +4 more
openaire   +4 more sources

Biomarkers for anti‑vascular endothelial growth factor drugs

Oncology Letters, 2022
Angiogenesis is regulated by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors. VEGF-A, VEGF-D, placental growth factor (PlGF) and plasminogen activator inhibitor-1 (PAI-1) have tumor angiogenic activity. VEGF-A and PAI-1 levels in the blood may impact the activity of bevacizumab, and VEGF-D levels may similarly ...
Kuriyama, Sho, Yamada, Takeshi, Matsuda, Akihisa, Takahashi, Goro, Iwai, Takuma, Takeda, Kohki, Ueda, Koji, Miyasaka, Toshimitsu, Yokoyama, Yasuyuki, Shinji, Seiichi, Sonoda, Hiromichi, Ohta, Ryo, Yonaga, Kazuhide, Kanaka, Shintaro, Yoshida, Hiroshi   +14 more
openaire   +2 more sources